Patterns of healthcare resource utilization in patients with sarcoidosis: a cross-sectional study.: Healthcare resource utilization in sarcoidosis.

Patterns of healthcare resource utilization in patients with sarcoidosis: a cross-sectional study.

Healthcare resource utilization in sarcoidosis.

Authors

  • Nynke Kampstra Department of Value-Based Healthcare, St. Antonius Hospital, Santeon-group. Radboud university medical center , Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare (IQ healthcare), Nijmegen, the Netherlands.
  • Paul B. van der Nat Department of Value-Based Healthcare, St. Antonius Hospital, Nieuwegein, the Netherlands. Radboud university medical center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare (IQ healthcare), Nijmegen, the Netherlands.
  • Frouke T. van Beek Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Jan C. Grutters Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands. Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands
  • Philip J. van der Wees Radboud university medical center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare (IQ healthcare), Department of Rehabilitation.

Keywords:

Sarcoidosis, Costs, Quality of Care

Abstract

Background: Limited data are available on healthcare resource use and costs in patients with sarcoidosis.

Objectives: The primary aim of this study was to describe cost-drivers of the top 1% and top ≥1-5% high-cost patients with sarcoidosis. The secondary aim was to compare costs of patients with and without fatigue complaints and to compare comorbidities.

Methods: We conducted a retrospective observational cross-sectional study in 200 patients diagnosed with sarcoidosis. Hospital administrative databases were used to extract healthcare utilization on the individual patient level. Healthcare costs were categorized into nine groups.

Results: Average total health care costs for the top 1% (n=22), top ≥1%–5% (n=88) and bottom 95% beneficiaries (n=90) were € 108.296, €53.237 and €4.817, respectively. Mean treatment time in days for the top 1%, top ≥1-5% and the random sample of the bottom 95% was 1688 days (±225), 1412 days (±367) and 775 days (±659), respectively. Mean annual costs for the top 1%, top ≥1-5% and the random sample of the bottom 95% are €51.082, €27.840 and €8.692, respectively. We identified three cost-drivers in the top 5% high-cost patients: 1) expensive medication, 2) intensive care and 3) costs made at the respiratory unit. Patients with and without fatigue showed to have comparable mean costs. High-cost patients were more likely to have multiple organs involved due to sarcoidosis.

Conclusions: We identified expensive medication as the main cost-driver in the top 5% high-cost patients with sarcoidosis. The study findings can help to tailor interventions for improving the quality of care and reducing overall costs.

Downloads

Published

30-09-2020

Issue

Section

Original Articles: Clinical Research

How to Cite

1.
Kampstra N, van der Nat PB, van Beek FT, Grutters JC, van der Wees PJ. Patterns of healthcare resource utilization in patients with sarcoidosis: a cross-sectional study.: Healthcare resource utilization in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2020 Sep. 30 [cited 2025 May 21];37(3):e2020002. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/9261